Mendus AB (publ)

SSE:IMMU.ST

0.47 (SEK) • At close February 20, 2024
Bedrijfsnaam Mendus AB (publ)
Symbool IMMU.ST
Munteenheid SEK
Prijs 0.469
Beurswaarde 316,541,088
Dividendpercentage 0%
52-weken bereik 0.3 - 2.045
Industrie Biotechnology
Sector Healthcare
CEO Dr. Erik Manting Ph.D.
Website https://www.mendus.com

An error occurred while fetching data.

Over Mendus AB (publ)

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's

Vergelijkbare Aandelen

Bio-Works Technologies AB (publ) logo

Bio-Works Technologies AB (publ)

BIOWKS.ST

4.85 SEK

InDex Pharmaceuticals Holding AB (publ) logo

InDex Pharmaceuticals Holding AB (publ)

INDEX.ST

0.244 SEK

Oncopeptides AB (publ) logo

Oncopeptides AB (publ)

ONCO.ST

7.264 SEK

Iconovo AB (publ) logo

Iconovo AB (publ)

ICO.ST

7.94 SEK

FluoGuide A/S logo

FluoGuide A/S

FLUO.ST

55.6 SEK

Stille AB logo

Stille AB

STIL.ST

160.5 SEK

Episurf Medical AB (publ) logo

Episurf Medical AB (publ)

EPIS-B.ST

0.98 SEK

Financiële Gegevens

Cijfers zijn in miljoenen (SEK)

Cijfers zijn in miljoenen (SEK)